Openbookopenbook
Equity
Royalty Pharma Plc(RPRX)
USD --+0.00%
Reward51Moderate
Risk33Moderate
75%Data
Strong 32% profit margin · Revenue growing 17% YoY
RPRX
+0.0 · +0.00%
USD · NASDAQ
Royalty Pharma Plc | Healthcare
Quality Compounder
Market Cap:33.86Bn
ⓘ
Reward Rating
51
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
33
Moderate
Risk Assessment
3 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RPRX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for RPRX, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $64.75.

What is Royalty Pharma Plc?

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.

RPRX · Verdict

Moderate reward · moderate risk

RPRX stands out on cash flow and profitability, but watch the valuation signal.

Based on 88% data coverage

RPRX · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow92/100

    105% free-cash-flow margin

  • Profitability90/100

    32% net margin · 14% ROE

  • Volatility80/100

    Top decile vs peers

Watchouts 2

  • Valuation11/100

    P/E 45.5× · PEG 2.07

  • Balance sheet32/100

    Interest covered 5.3×

Model-based scoring. For information only — not financial advice.

What is Royalty Pharma Plc?

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 33.86B, and a P/E ratio of 31.5x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (51)

The scoring profile indicates limited reward potential at this time, with profitability and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap33.86B
P/E Ratio31.5054
Dividend Yield1.56%
Beta0.425
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
3104,373 shares
$4.9M
0
6-9months
17743,863 shares
$29.9M
0
9-12months
0
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.